WuXi Biologics Receives The Asset ESG Corporate Platinum Award for Third Consecutive Year
Shanghai, October 31, 2023 – WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has received a Platinum Award from The Asset ESG Corporate Awards for the third year in a row. The honor recognizes the company’s adherence to ESG principles and is a reflection of its deep commitment to sustainability.
The Asset, a widely recognized business news and research organization, evaluates companies regarding their ESG responsibilities for its annual ESG Corporate Awards, reviewing a wide range of metrics, including energy consumption and GHG emissions, waste and water management, supplier codes of conduct, sustainability financing, and corporate governance. WuXi Biologics is the only biologics CRDMO company among the winners.
Dr. Chris Chen, WuXi Biologics CEO and Chairman of the ESG Committee, commented, “We are very pleased to receive a Platinum Award from The Asset for the third time, a demonstration of WuXi Biologics’ industry-leading ESG performance. Our ESG commitments and efforts were widely recognized by multiple rating agencies and index providers during the past year. We appreciate the trust and support of our global partners, investors and local communities, and will continue to enhance our ESG capabilities – through comprehensive strategy and refined initiatives – for a sustainable future and for the benefit of patients worldwide.”
WuXi Biologics regards sustainability as the cornerstone of its business development strategy. In 2023, notable progress was made particularly on the ESG material issues of climate change; diversity, equity, and inclusion (DEI); responsible governance; and sustainable procurement. This May, the company established a DEI Committee as the highest-level management body to oversee and further advance DEI efforts. In June, it announced the signing of the Science Based Targets initiative (SBTi) commitment letter, marking a new milestone in the company’s net-zero efforts. Additionally, in September, WuXi Biologics became a signatory of the United Nations Global Compact (UNGC), which demonstrates its commitment to sustainable and socially responsible policies.
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of June 30, 2023, WuXi Biologics is supporting 621 integrated client projects, including 22 in commercial manufacturing.
WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to become an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.
For more information about WuXi Biologics, please visit: www.wuxibiologics.com.